尋常性白斑 - 市場洞察、疫学、市場予測 2028年
Vitiligo - Market Insights, Epidemiology, and Market Forecast-2028
|発行||DelveInsight Business Research LLP||商品コード||703503|
|出版日||ページ情報||英文 143 Pages
|尋常性白斑 - 市場洞察、疫学、市場予測 2028年 Vitiligo - Market Insights, Epidemiology, and Market Forecast-2028|
|出版日: 2019年08月01日||ページ情報: 英文 143 Pages||
DelveInsight's 'Vitiligo - Market Insights, Epidemiology, and Market Forecast-2028' report deliver an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Vitiligo in the United States, EU5 (Germany, Spain, Italy, France and the United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of Vitiligo from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess the underlying potential of the market.
Study Period: 2017-2028
The DelveInsight Vitiligo market report gives a thorough understanding of the Vitiligo by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Vitiligo in the US, Europe, and Japan.
The Vitiligo epidemiology division provide insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Prevalence of Vitiligo in 7MM, Total Diagnosed Prevalence of Vitiligo in 7MM, Gender-specific Prevalence of Vitiligo in 7MM, Age-specific Diagnosed Prevalence of Vitiligo in 7MM, and Type-specific Diagnosed Prevalence of Vitiligo in 7MM) scenario of Vitiligo in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.
According to DelveInsight, the total number of prevalent population of Vitiligo was found to be 6,234,655 in 7MM in the year 2017.
This segment of the Vitiligo report encloses the detailed analysis of late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
At present, the therapeutic market Size of Vitiligo in the United States is mainly accounted for by the off-label use of Corticosteroids and Calcineurin inhibitors, both as monotherapy as well as combination therapies. These therapies are also combined with Phototherapy (phototherapy as a monotherapy is not included in the market size estimation) for treating Vitiligo and, the market size of Vitiligo in the United States is inclusive of the revenue generated by these combination therapies [i.e., Corticosteroids + Calcineurin inhibitors and Corticosteroids + Calcineurin inhibitors + Phototherapy].
Topical Corticosteroids and calcineurin inhibitors constitute the first line of treatment for Vitiligo. Both of these therapies act by diminishing the cellular immune response.
However, the most significant combinational therapy, that contributes the most toward the market size, is a combination of Corticosteroids, calcineurin inhibitors, and Phototherapy. Although the patient share opting for this combination, is quite nominal, however, the higher cost of treatment is the main reason behind a large amount of market revenue generated by the combined usage of these therapies.
The above-mentioned off-label therapies currently hold the market of Vitiligo in the United States. However, the dynamics of Vitiligo market is anticipated to change during the forecasted period. Companies have shifted their focus on the development of targeted treatment for Vitiligo, (mostly JAK inhibitors) and owing to the expected launch of emerging therapies during the forecasted period of (2019-2028), the market size is expected to increase in subsequent years.
The Vitiligo market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the market of Vitiligo in 7MM was found to be USD 882.75 million in 2017 and is expected to increase at a CAGR of XX% from 2017-2028.
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.